Superworth

Harvard Bioscience free cash flow HBIO

Cash from operations less capital spending, by quarter and over the last twelve months, from 2017.

Last 12 months, to Jun 30, 2026
−$1.1M
Latest quarter, Q2 FY26
−$363K
−114% on a year earlier
Fiscal year 2025
$5.5M

Harvard Bioscience's free cash flow was −$1.1M over the twelve months to Jun 30, 2026, down 123% on a year earlier.

In its latest quarter, Q2 FY26, it was −$363K, down 114% on the same quarter a year before.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025$5.5Mn/a
FY2024−$1.2M−110%
FY2023$12.2Mn/a
FY2022−$438K−754%
FY2021$67K−99%
FY2020$8.2M+20%
FY2019$6.8M+260%
FY2018$1.9M+1037%
FY2017$167Kn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$363K−114%−$1.1M
Q1 FY26−$1.1M−144%$1.9M
Q4 FY25−$545K−138%$5.5M
Q3 FY25$877Kn/a$7.4M
Q2 FY25$2.7Mn/a$4.8M
Q1 FY25$2.5M+226%$511K
Q4 FY24$1.4M−59%−$1.2M
Q3 FY24−$1.7M−142%$845K
Q2 FY24−$1.7M−155%$6.7M
Q1 FY24$758K−52%$11.4M
Q4 FY23$3.5M+42%$12.2M
Q3 FY23$4.1M+1902%$11.2M

Against its peers

Companies in Healthcare nearest Harvard Bioscience's size, closest first, today.

CompanyFree cash flow yield
HBIOHarvard Bioscience−3.0%
NEPHNephrosn/m
ATNMActinium Pharmaceuticalsn/m
APTAlpha Pro Tech10.3%
SPROSpero Therapeuticsn/m
LFVNLifevantage9.1%
ICCCImmucell4.5%
KEQUKewaunee Scientific11.5%
PDEXPro DEX3.4%
PLXProtalix BioTherapeutics3.7%
NATRNatures Sunshine Products8.5%
Peer median8.5%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Harvard Bioscience

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.